McCarty M F
Nutrition 21, San Diego, CA 92109, USA.
Med Hypotheses. 1999 Oct;53(4):300-4. doi: 10.1054/mehy.1997.0761.
Reports from several research groups--including two small double-blind clinical studies--indicate that supplemental coenzyme Q10 (CoQ) is moderately effective as a treatment for hypertension, in humans and in animals. Its efficacy is associated with a decrease in total peripheral resistance, and appears to reflect a direct impact of CoQ on the vascular wall. A reasonable interpretation of these findings is that CoQ is acting as an antagonist of vascular superoxide--either scavenging it, or suppressing its synthesis. By improving the efficiency of shuttle mechanisms that transfer high-energy electrons from the cytoplasm to the mitochondrial respiratory chain, CoQ may decrease cytoplasmic NADH levels and thereby diminish the reductive power that drives superoxide synthesis in endothelium and vascular smooth muscle. If CoQ therapy does indeed lower vascular superoxide levels, it can be expected to decrease the atherothrombotic risk associated with hypertension, and may have broader utility in the management of disorders characterized by endotheliopathy.
包括两项小型双盲临床研究在内的多个研究小组的报告表明，补充辅酶Q10（CoQ）对治疗人类和动物的高血压有一定疗效。其疗效与总外周阻力降低有关，似乎反映了CoQ对血管壁的直接影响。对这些发现的一个合理的解释是，CoQ作为血管超氧化物的拮抗剂——要么清除它，要么抑制其合成。通过提高将高能电子从细胞质转移到线粒体呼吸链的穿梭机制的效率，CoQ可能会降低细胞质NADH水平，从而减少驱动内皮细胞和血管平滑肌中超氧化物合成的还原能力。如果CoQ疗法确实能降低血管超氧化物水平，那么可以预期它会降低与高血压相关的动脉粥样硬化血栓形成风险，并且可能在以内皮病变为特征的疾病管理中有更广泛的用途。
